#United States #Maryland #class action lawsuit #Pomerantz #Regencell Bioscience

Class Action Lawsuit Filed Against Regencell Bioscience

The Pomerantz Law Firm has recently announced the commencement of a class action lawsuit against Regencell Bioscience Holdings Limited. This legal action was filed in the United States District Court for the District of Maryland, and it seeks to address significant claims regarding violations of federal securities laws by Regencell and certain of its executives.

The class action is on behalf of individuals and entities that purchased securities of Regencell within a specified time frame, from October 28, 2024, to October 31, 2025. The lawsuit aims to recover losses incurred due to the alleged misconduct of the defendants, with the Pomerantz Law Firm asserting that Regencell made several materially false and misleading statements regarding its business, operations, and compliance policies.

Background on Regencell Bioscience

Regencell positions itself as a pioneering early-stage company focused on the research, development, and commercialization of traditional Chinese medicine for treating conditions such as Attention-Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD). Despite being in a highly competitive field, the company claims its approach seeks to address the root causes of neurocognitive disorders rather than merely alleviating symptoms.

However, the company’s stock history reveals a troubling pattern. Regencell's shares were initially trading at under 30 cents but experienced an astonishing surge to a high of $78.00 in June 2025, representing a staggering increase of nearly 48,650% since the start of the class period. Following this peak, the stock price quickly fell to around $27-$29, indicating a volatile market situation that raises concerns about potential manipulation.

Allegations of Securities Violations

The Class Action lawsuit filed by Pomerantz highlights several key allegations:
1. Market Vulnerability: It claims that Regencell was susceptible to market manipulation, which significantly affected its stock price volatility, exposing investors to financial risks.
2. Lack of Transparency: The company allegedly failed to disclose the risks associated with its trading practices and the consequent implications for its investors.
3. False Statements: The class action accuses the company's officials of making misleading statements that did not accurately reflect Regencell’s vulnerabilities or the true nature of their operations.

The lawsuit also notes that Regencell faced a growing risk of regulatory scrutiny, especially following an increase in legal and operational challenges coinciding with the stock's volatility and drastic price fluctuations.

In a notable exchange with the U.S. Securities and Exchange Commission, Regencell acknowledged that it received a subpoena from the Department of Justice, indicating ongoing investigations about potential issues concerning its stock trading practices.

What This Means for Investors

For those investors who believe they have experienced losses attributable to these alleged securities violations, there is a window of opportunity to act. The Pomerantz Law Firm informs potential class members that they must express their intent to be named as Lead Plaintiff by June 23, 2026. Information about this lawsuit can be obtained from their official website, where the complaint details are also published.

As investors navigate this unfolding situation, the implications of the lawsuit could resonate widely across the biotech investment landscape, particularly concerning companies operating under similar conditions where stock price manipulation could pose significant risks.

Conclusion

The class action against Regencell Bioscience Holdings serves as an important reminder of the complexities involved in investing in emerging biotech firms, especially those that may face internal and external pressures that affect their market performance. With Pomerantz Law Firm leading the charge to recover losses for affected investors, this case could potentially mark a pivotal moment in addressing accountability within the biotech sector.

For more information, investors are encouraged to reach out to Pomerantz LLP or consult the detailed complaint available online.